Essential Thrombocythemia: Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects
With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
What is the safety, tolerability and effectiveness of
ruxolitinib compared to anagrelide in patients with Essential Thrombocythemia who
are resistant or intolerant to hydroxyurea?
Basic Study Information
Purpose:Location: Cancer Center
This study has two groups. The first group, Group A, will be treated with ruxolitinib
and placebo and the second group, Group B, will be treated with anagrelide and placebo.
You will be randomly assigned (like flipping a coin) to Group A or Group B. Neither
you nor your Study Doctor can identify which group you will be assigned to. You will
have equal chance of receiving ruxolitinib or anagrelide.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT03123588?term=INCB+18424-272&rank=1 https://clinicaltrials.gov/ct2/show/NCT03123588?term=INCB+18424-272&draw=1&rank=1
Study Reference #: IHEM17035
Lead Researcher (Principal Investigator)
Lead Researcher: Frank Akwaa
Study Contact InformationStudy Coordinator: Brandon DeLorme
Phone: (585) 275-5295
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search